Press Releases June 4, 2026 08:30 AM

Bakkt Advances Indian Investment Following Regulatory Approval

Bakkt secures regulatory approval to advance strategic investment in Indian financial services firm Transchem Limited

By Sofia Navarro BKKT

Bakkt, Inc. has received the necessary regulatory approvals from Indian authorities to proceed with its $9.4 million investment in Transchem Limited, a significant player in India's financial services sector. This strategic move positions Bakkt to capitalize on the rapidly growing Indian financial market and fintech ecosystem, including potential acquisitions to expand brokerage and depository services under Indian regulations. Bakkt aims to support Transchem's growth and strengthen its own global infrastructure for the future of finance.

Bakkt Advances Indian Investment Following Regulatory Approval
BKKT

Key Points

  • Bakkt completed allotment of 47.5 million warrants in Transchem, representing a substantial investment in the Indian market.
  • Transchem is exploring acquisition opportunities of SEBI-regulated stockbroking and depository participant businesses to expand its footprint.
  • India's expanding fintech ecosystem with rapidly growing equity investors presents significant growth potential for regulated financial infrastructure providers like Bakkt.

ATLANTA, June 04, 2026 (GLOBE NEWSWIRE) -- Bakkt, Inc. (“Bakkt,” or “the Company”) (NYSE: BKKT) today announced that it has received the required Indian regulatory approvals in connection with its previously disclosed strategic investment in Transchem Limited (BSE: 500422) (“Transchem”). Following receipt of such approvals, Transchem has completed the allotment of 47,500,000 warrants to Bakkt, for which Bakkt paid approximately $9.4 million, representing 25% of the total subscription amount.

“We believe India represents one of the most compelling opportunities globally at the intersection of financial infrastructure, capital markets, and digital innovation,” said Akshay Naheta, Chief Executive Officer of Bakkt. “India today serves more than 136 million equity investors, continues to add significant numbers of new market participants every day, and has developed one of the world's most advanced fintech ecosystems. As the market continues to mature, we believe the demand for regulated financial infrastructure, brokerage services, and next-generation financial products will continue to grow. We look forward to supporting Transchem as it executes on its strategic vision and pursuing opportunities to create long-term value for shareholders.”

Transchem has previously informed Bakkt that it is evaluating opportunities to expand its presence in India’s financial services sector, including through a potential acquisition of a SEBI-regulated stockbroking and depository participant business. Any such transaction would remain subject to customary regulatory, corporate, and other approvals.

Bakkt expects to provide further updates regarding its investment and related strategic initiatives as additional milestones are achieved.

Additional information regarding the investment is included in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission today and available on the investor relations section of Bakkt’s website.

About Bakkt
Founded in 2018, Bakkt, Inc. is a regulated financial technology company building infrastructure for the future of finance. Bakkt’s platform serves financial institutions, fintechs, and consumer finance products — providing the compliance, security, and scale required to deliver trusted financial services at a global level. Through its core business pillars, Bakkt powers institutional-grade trading capabilities, AI-enabled programmable finance, and cross-border payment infrastructure.

Bakkt is headquartered in Atlanta, GA. For more, visit: Bakkt | X | LinkedIn | Instagram

Investor Relations
OG Advisory Group
Yujia Zhai
[email protected]

Media
Luna PR
[email protected]

Note on Forward-Looking Statements
This release and accompanying remarks contain “forward-looking statements” within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as “will,” “likely,” “expect,” “continue,” “anticipate,” “estimate,” “believe,” “intend,” “plan,” “projection,” “outlook,” “grow,” “progress,” “potential” or other variations of these terms, as well as similar expressions that discuss future plans, actions, or events. The absence of such words does not mean that a statement is not forward-looking. These statements are based on the current beliefs and expectations of Bakkt, Inc. (the “Company”) and are inherently subject to significant business, economic, and competitive uncertainties and contingencies — many of which are difficult to predict and are beyond the Company’s control.

Forward-looking statements in this release may include, for example, statements about: the Company’s strategic investment in Transchem Limited and the anticipated benefits thereof; the Company’s expectations regarding the issuance of warrants by Transchem Limited; the Company’s expectations regarding the exercise of the warrants and any payment thereunder; the Company’s expectations regarding Transchem Limited’s identification of a potential broker-dealer acquisition target and the consummation of any related transaction; the Company’s expectations regarding any potential corporate name change or rebranding of Transchem Limited and expected changes to its management and governance; the Company’s ability to expand into international markets, including India; the expansion of the Bakkt Global business engine; and assumptions underlying any of the foregoing, including with respect to market conditions, regulatory and partnership developments, and the Company’s ability to execute its strategies.

Actual results and the timing of events may differ materially from those anticipated due to a number of factors, including but not limited to: changes in the regulatory environment in India, the United States, and other jurisdictions in which the Company operates; the Company’s ability to satisfy applicable requirements under Indian foreign exchange and securities regulations; fluctuations in the U.S. dollar / Indian rupee exchange rate; changes in the market price of Transchem Limited’s ordinary shares listed on BSE Ltd.; the Company’s ability to elect to exercise the warrants and fund the remaining 75% of the exercise price within the 18-month exercise window; the failure of Transchem Limited to identify, negotiate, or consummate the previously disclosed potential acquisition of an Indian broker-dealer and depository participant; the inability to consummate any potential corporate name change or rebranding of Transchem Limited or expected changes to its management and governance; risks associated with the Company’s investments in companies listed on non-U.S. exchanges; and other factors described in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”), including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

These and other risks are detailed in the Company’s filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements. These statements speak only as of the date of this release, and Bakkt undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.


Risks

  • Regulatory risks related to satisfying Indian foreign exchange and securities laws and ongoing compliance with Indian authorities.
  • Uncertainty around Transchem's ability to successfully execute potential acquisitions and expand its presence in the Indian financial services sector.
  • Foreign exchange risks due to fluctuations between the US dollar and Indian rupee impacting investment costs and returns.

More from Press Releases

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions Jun 4, 2026 Telesat announces results of 2026 Annual General Meeting of shareholders Jun 4, 2026 TOMI Expands European Footprint with New Regulatory Approvals for Binary Ionization Technology Jun 4, 2026 Xos Makes Its GFX Debut with Electric Vehicles, Powertrain Technology, and Mobile Charging for Public Fleets Jun 4, 2026 Satellogic to Participate in June Investor Conferences Jun 4, 2026